RedHill Biopharma has finished patient enrolment in a Phase III clinical trial (MAP US) of RHB-104 being evaluated for the treatment of Crohn’s disease.

Formulated for oral administration, RHB-104 is an antibiotic combination therapy said to possess intracellular, anti-mycobacterial and anti-inflammatory properties.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Being conducted at around 150 clinical sites across the US, Canada, Europe, Israel, Australia and New Zealand, the randomised, double-blind, placebo-controlled Phase III trial enrolled a total of 331 subjects.

Designed to investigate the safety and efficacy of RHB-104 in patients suffering from moderate to severely active Crohn’s disease, the trial will assess disease remission as the primary endpoint.

“Patients will be treated for an additional period of 52 weeks during the extension study, with its primary endpoint being disease remission at week 16.”

The firm is also conducting an open-label extension Phase III MAP US2 study to monitor the safety and efficacy of RHB-104 in subjects who remain with active Crohn’s disease following 26 weeks of treatment in the MAP US trial.

Patients will be treated for an additional period of 52 weeks during the extension study, with its primary endpoint being disease remission at week 16.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The MAP US2 study is set to recruit about 50-70 patients in the US, Canada, Europe, Israel, and New Zealand.

Top-line results from the Phase III MAP US trial are scheduled to be available mid-2018, with plans for additional open-label studies to support future marketing applications of RHB-104.

In the first half of next year, RedHill Biopharma intends to commence a Phase III trial of RHB-104 for treating non-tuberculous mycobacteria (NTM) infections in the US.